Foghorn Therapeutics Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Foghorn Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Foghorn Therapeutics Inc. Debt-to-equity for the quarter ending September 30, 2024 was -642 %, a 46.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -642 +548 +46.1% Sep 30, 2024
Q2 2024 -580 +2.65K +82.1% Jun 30, 2024
Q1 2024 -524 -3.94K -115% Mar 31, 2024
Q4 2023 -729 -1.86K -164% Dec 31, 2023
Q3 2023 -1.19K -1.88K -273% Sep 30, 2023
Q2 2023 -3.23K -3.69K -812% Jun 30, 2023
Q1 2023 3.41K +3.12K +1054% Mar 31, 2023
Q4 2022 1.13K +954 +527% Dec 31, 2022
Q3 2022 687 +594 +641% Sep 30, 2022
Q2 2022 454 +282 +163% Jun 30, 2022
Q1 2022 296 Mar 31, 2022
Q4 2021 181 Dec 31, 2021
Q3 2021 92.8 Sep 30, 2021
Q2 2021 172 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.